Literature DB >> 10202110

Induction of apoptosis in activated T cell blasts by suppressive macrophages: a possible immunotherapeutic approach for treatment of autoimmune disease.

K R McIntosh1, D B Drachman.   

Abstract

Large suppressive macrophages (LSM) were induced by restimulating spleen cells from rats with experimental autoimmune myasthenia gravis (EAMG) in vitro, with the autoantigen acetylcholine receptor (AChR) in the presence of cyclosporine A. LSM, purified from these cultures, are extremely potent suppressors of AChR-stimulated lymphoproliferative responses and antibody responses in vitro. In the present study, we have analyzed the factors that determine susceptibility of primed lymph node cells (pLNC) to suppression by LSM and examined the fate of these cells. We found three characteristics of pLNC that influenced their susceptibility to suppression. First, pLNC were required to be activated (by antigen in these experiments) in order for suppression to occur. Resting lymphocytes were not affected, even when they were present in cultures where antigen-activated lymphoblasts were being actively suppressed. Second, antigen specificity of the responder cells influenced their susceptibility to suppression by LSM. AChR-specific cells were relatively more susceptible to suppression by AChR-induced LSM than pLNC primed to an unrelated antigen, keyhole limpet hemocyanin. Third, T cell proliferation was suppressed by LSM to a far greater extent than antibody production by B cells. Using enriched T cell blasts generated from AChR-stimulated T cell lines, we found that LSM rapidly suppressed [3H]TdR uptake and induced DNA fragmentation assessed by the TUNEL assay (within 8 h of coculture) and induced morphological signs of apoptosis of T cells (within 24 h). Few, if any, blasts remained by 48 h of coculture. The ability to suppress an activated immune response permanently, without affecting nonactivated, bystander lymphocytes, holds promise that LSM, or their cellular products, could be used for immunotherapy of autoimmune diseases such as myasthenia gravis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202110     DOI: 10.1006/cimm.1998.1445

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

Review 1.  MDSC in autoimmunity.

Authors:  James G Cripps; James D Gorham
Journal:  Int Immunopharmacol       Date:  2011-02-21       Impact factor: 4.932

2.  Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells.

Authors:  Vrajesh V Parekh; Lan Wu; Danyvid Olivares-Villagómez; Keith T Wilson; Luc Van Kaer
Journal:  J Immunol       Date:  2013-01-23       Impact factor: 5.422

3.  Infection of human monocyte-derived macrophages with Chlamydia trachomatis induces apoptosis of T cells: a potential mechanism for persistent infection.

Authors:  M C Jendro; T Deutsch; B Körber; L Köhler; J G Kuipers; B Krausse-Opatz; J Westermann; E Raum; H Zeidler
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 4.  The Role and Potential Therapeutic Application of Myeloid-Derived Suppressor Cells in Allo- and Autoimmunity.

Authors:  Qi Zhang; Masayuki Fujino; Jinhua Xu; Xiao-kang Li
Journal:  Mediators Inflamm       Date:  2015-05-19       Impact factor: 4.711

Review 5.  Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.

Authors:  Francesca Maria Consonni; Chiara Porta; Arianna Marino; Chiara Pandolfo; Silvia Mola; Augusto Bleve; Antonio Sica
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 6.  Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models.

Authors:  Xueli Fan; Hongliang Zhang; Yun Cheng; Xinmei Jiang; Jie Zhu; Tao Jin
Journal:  Mediators Inflamm       Date:  2016-03-13       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.